{"name":"Myovant Sciences","slug":"myovant","ticker":"MYOV","exchange":"NYSE (acquired by Sumitomo Pharma)","domain":"myovant.com","description":"Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.","hq":"Brisbane, CA (subsidiary of Sumitomo Pharma, Osaka, Japan)","founded":0,"employees":"","ceo":"David Marek","sector":"Women's Health / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"N/A (Sumitomo subsidiary)","metrics":{"revenue":680000000,"revenueGrowth":289.4,"grossMargin":0,"rdSpend":107403000,"netIncome":-205981000,"cash":520011000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[{"name":"Orgovyx","genericName":"relugolix","slug":"relugolix","revenue":421000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2020-01-01","label":"Orgovyx first approved","drug":"Orgovyx","drugSlug":"relugolix","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2033-09-27","label":"Orgovyx patent expiry (Compound)","drug":"Orgovyx","drugSlug":"relugolix","type":"patent_expiry","sentiment":"negative"},{"date":"2033-09-27","label":"Orgovyx patent expiry (Compound)","drug":"Orgovyx","drugSlug":"relugolix","type":"patent_expiry","sentiment":"negative"},{"date":"2037-09-29","label":"Orgovyx patent expiry (Method of Use)","drug":"Orgovyx","drugSlug":"relugolix","type":"patent_expiry","sentiment":"negative"},{"date":"2037-09-29","label":"Orgovyx patent expiry (Method of Use)","drug":"Orgovyx","drugSlug":"relugolix","type":"patent_expiry","sentiment":"negative"},{"date":"2037-09-29","label":"Orgovyx patent expiry (Method of Use)","drug":"Orgovyx","drugSlug":"relugolix","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"relugolix patent cliff ($1.4B at risk)","drug":"relugolix","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":421000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Orgovyx","genericName":"relugolix","slug":"relugolix","indication":"Abnormal uterine bleeding due to uterine fibroid","status":"marketed","revenue":421000000}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Estradiol/norethindrone acetate","genericName":"Estradiol/norethindrone acetate","slug":"estradiol-norethindrone-acetate","indication":"Moderate to severe vasomotor symptoms associated with menopause","status":"marketed"},{"name":"Placebo for relugolix","genericName":"Placebo for relugolix","slug":"placebo-for-relugolix","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Orgovyx","genericName":"relugolix","slug":"relugolix","phase":"marketed","mechanism":"Relugolix is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors.","indications":["Abnormal uterine bleeding due to uterine fibroid","Lower abdominal pain","Malignant tumor of prostate","Menorrhagia","Pain associated with endometriosis"],"catalyst":""},{"name":"Estradiol/norethindrone acetate","genericName":"Estradiol/norethindrone acetate","slug":"estradiol-norethindrone-acetate","phase":"marketed","mechanism":"Estradiol and norethindrone acetate work together as a hormone replacement therapy, with estradiol providing estrogen and norethindrone acetate providing progestin to supplement declining hormones.","indications":["Moderate to severe vasomotor symptoms associated with menopause","Moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause"],"catalyst":""},{"name":"Placebo for relugolix","genericName":"Placebo for relugolix","slug":"placebo-for-relugolix","phase":"phase_3","mechanism":"A placebo control contains no active pharmaceutical ingredient and serves as a comparator in clinical trials to establish the efficacy of relugolix.","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"FDA Approves Myovant Sciences' Relugolix Combination Therapy for Endometriosis","summary":"The FDA approved relugolix combination therapy for the treatment of moderate to severe pain associated with endometriosis.","drugName":"relugolix combination therapy","sentiment":"positive"},{"date":"2022-12-15","type":"earnings","headline":"Myovant Sciences Reports Third Quarter 2022 Financial Results","summary":"Myovant Sciences reported revenue of $143.4 million for the third quarter of 2022, a 24% increase from the same period in 2021.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix Combination Therapy","summary":"Myovant Sciences and Pfizer announced a collaboration to develop and commercialize relugolix combination therapy for the treatment of uterine fibroids and endometriosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE5YYk1oMlF4NWp3cjFYNGh5VUsxdnZIa1NPUEZ4ZVpzRjJHX1Q2ckQwNklFLWtxc2hDR05wMHp0dG1NT3RHZWFMTmpSN2ZjZWNSZ092aXZHTUhTOVkxR2JVTkE1bW1BUE5XWXdCQWtoQmtVUQ?oc=5","date":"2023-03-13","type":"deal","source":"Femtech Insider","summary":"Sumitovant Biopharma Acquires Women’s Health Pharma Company Myovant Sciences for $1.7B - Femtech Insider","headline":"Sumitovant Biopharma Acquires Women’s Health Pharma Company Myovant Sciences for $1.7B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQdVpSWkx4dlBDRGdiSDlKVjhLcmluSDN6d20xaEVuWmhVQzNwMGJvSy1DZ1VKeVVld1lGMzdUQWNRdzZQQTF0bm1rR2xQeFN5VW9SYUZ1ZFkzelBmQnNaSGtSRUtQeWRvU3p1azVGNUdFdUtxQThMaVZLSkFpOXJfTm9zUjFNemlvS3ppV1N3YzluS3FtNnN6cVBDcWpxSFAwYmxZc0JFenA5ZXVxOVRMMWpMMS1wU2dsM3c?oc=5","date":"2023-03-10","type":"pipeline","source":"PR Newswire","summary":"Sumitovant Biopharma Completes Acquisition of Myovant Sciences - PR Newswire","headline":"Sumitovant Biopharma Completes Acquisition of Myovant Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPX28tRkk3bUg2cWJhMk0ybzFyVzhsbFNFQjZLQjV0ZnRRdXk5Vm9PTVByMEwtNG51N21WZV9kQldyUjczX3NIRFJCRVBQYXJvSE5xdk93UXBBcjFMN2JFeEZlZTk5Q2JqR0xYelJzaG9GX0dJc0hkVjd4MFVrTEIzcHdR?oc=5","date":"2022-10-24","type":"deal","source":"BioPharma Dive","summary":"Myovant agrees to sell after buyer ups price - BioPharma Dive","headline":"Myovant agrees to sell after buyer ups price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQVC0ybGZhNXUwWk5uUXlwLXotZk1Kb0xkbUtva25XSEtHYm9udG9IMTRkNnhPYjhJb05Vd25zUzEtTW5pek5EMTFaNjNoOXhTcEFwRk1KYU1uZUowdXlSdzRQMlpjTXdENEExWjVrd1lwQVhwMnpJQV9iNzkwc2FqbzVnMl84emhxS1hUbjNsT2pDeEhWc0txc05CMHNKb2pGaWN5Wg?oc=5","date":"2022-10-24","type":"pipeline","source":"BioSpace","summary":"Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant - BioSpace","headline":"Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUW4ybXdmX2dtb0xSZ0tBeF8tZmhaMXlzZ081enduWm9lMFlzaC1pVlRLeExtaUtyVEhYNzdzbWVjVzhKTjJxczFUcXRXNE5FeWxWN1RtMWVOUTFZLUxjaC1jdDhvc2JXZk5OT0N0TkhoejhSQ09aZG8xMDFCZlF3eUgwXzV3NVRmVXQxNnFMM0lSTDg1djJjaHNSdTNBRl95NWl3d1dLc1hVMmllX1U0a1pkWGluYjJieU4zNkMzTnkzaWpQc1RHR1E4QTdwTndBS3ViTGpGTmpGQmh2TUE?oc=5","date":"2022-10-23","type":"pipeline","source":"PR Newswire","summary":"Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement - PR Newswire","headline":"Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQd2tJX0RSRlRrdVNJM0c3QnptTEkwb1ZmOUxIejBVMkN5dDN3aVN2OTdvWGdCN0ZudXVrMW5NWDBuVjAyTkZrYXdlWWhVUlRpelhjcmxLLXQ1c0szbTRyaDhMNWVrVHpRTUdYNHVjRVVaemRRS3h1Wkk2S2V4bU1sb1lYVHA1WnRLRU1WWTE4b2R3RkluZEZneVBTTFdBVUd3c2tIb05R?oc=5","date":"2022-10-03","type":"deal","source":"Fierce Pharma","summary":"Myovant says no to Sumitomo's takeover bid but is open to negotiating a better deal - Fierce Pharma","headline":"Myovant says no to Sumitomo's takeover bid but is open to negotiating a better deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNWEt4SnNOMnNWamsxWkNfOWNaRTJocFpSaTdBWGI5SzR6UzBiNW9NMkN6Vi1HczBOTDM5WkV6enZvTkk2LW1HaHItaVpJVG5reEpvS3d1YjFFa08yRXRsQlU3QUsyc0c3QUlBbURoYWpnWTQ0QjJ2UThRX0Z6TWRoNkVCeUh3QUdxQjhOZ1k1bmxEMWswNTZwUkJ3c1hWYWxMNjFiMnJnbzVoX05rQjdPblVrQjEya1VQQ0hQMzJxbXVncDFnMlphdXNWa2Z5cUpHS3pyaWZ6dVJHcC1PVGhxR25hRjB0QXloTFkxTDA5MDlwMUE?oc=5","date":"2022-10-02","type":"deal","source":"PR Newswire","summary":"Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences - PR Newswire","headline":"Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQMUV3Q29oZHBsY21NSmdMYXVOZy1ZLTNNel9SMW5HSTVVSHB3OFFkNVN5SmFUT09fRF9EcHgxNVd1Z2pXQ1l5dU9aaHdtT0JwdWM1SF9jekYwM01Tdzl4bHhtS1VNWU96TmlIVGpybzMtdmJrRU5lNC03TWJyQkY5cTY1MGUwM3hYd0o3NVFfMGx1UFhJcFVNWlV5SGVxVG9WdmxfaThvalFzcjJGRzd6dERuQ2taN3lKQ3A0SC1pX0Q?oc=5","date":"2021-05-26","type":"regulatory","source":"Fierce Pharma","summary":"Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie - Fierce Pharma","headline":"Myovant and Pfizer's uterine fibroids med scores FDA nod, setting up showdown with AbbVie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPbnF1MnlOX1JSRUlxcHQzNHBBUThoRk5FODNnT0ZtM1pzczVXVmFTdEcxMGtvZUZQV0Q5d091OU5xYzc5cUt2eW1seWJaajFJOVY5LXBYSnhaMHRPcXVzNEkta2NYT1M0RGlHclFyUy1SZ1RNNGNwTi1iR2lDQUlRUGtFUTRiYk1hT2VfeThNTGc3WDZMZWdST21wekJNLTJnRTNOUw?oc=5","date":"2019-09-06","type":"deal","source":"The Business Journals","summary":"$3B package deal to push Peninsula company into arms of Japanese drugmaker - The Business Journals","headline":"$3B package deal to push Peninsula company into arms of Japanese drugmaker","sentiment":"neutral"}],"patents":[{"drugName":"relugolix","drugSlug":"relugolix","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Orgovyx","drugSlug":"relugolix","patentNumber":"11795178","type":"Compound","expiryDate":"2033-09-27","territory":"US","annualRevenue":421000000,"genericFilings":[]},{"drugName":"Orgovyx","drugSlug":"relugolix","patentNumber":"12325714","type":"Compound","expiryDate":"2033-09-27","territory":"US","annualRevenue":421000000,"genericFilings":[]},{"drugName":"Orgovyx","drugSlug":"relugolix","patentNumber":"12144809","type":"Method of Use","expiryDate":"2037-09-29","territory":"US","annualRevenue":421000000,"genericFilings":[]},{"drugName":"Orgovyx","drugSlug":"relugolix","patentNumber":"12336990","type":"Method of Use","expiryDate":"2037-09-29","territory":"US","annualRevenue":421000000,"genericFilings":[]},{"drugName":"Orgovyx","drugSlug":"relugolix","patentNumber":"12097198","type":"Method of Use","expiryDate":"2037-09-29","territory":"US","annualRevenue":421000000,"genericFilings":[]}],"drugCount":3,"phaseCounts":{"marketed":2,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["GSK","Pfizer","AbbVie"],"therapeuticFocus":["Women's Health","Oncology","Endocrine Diseases"],"financials":{"source":"sec_edgar","revenue":230972000,"revenuePeriod":"2022-03-31","revenueHistory":[{"value":230972000,"period":"2022-03-31"},{"value":59317000,"period":"2021-03-31"},{"value":59317000,"period":"2021-03-31"},{"value":0,"period":"2020-03-31"},{"value":0,"period":"2020-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":107403000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-205981000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":520011000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}